The full details of the definitive version are as follows:

TITLE: Long-term high fat feeding of rats results in increased numbers of circulating microvesicles with pro-inflammatory effects on endothelial cells

AUTHORS: Heinrich, LF; Andersen, DK; Cleasby, ME; Lawson, C

JOURNAL TITLE: British Journal of Nutrition

VOLUME/EDITION: 113/11

PUBLISHER: Cambridge University Press

PUBLICATION DATE: June 2015

DOI: 10.1017/S0007114515001117

Royal
Veterinary
College
University of London

Long-term high fat feeding of rats results in increased numbers of circulating microvesicles with pro-inflammatory effects on endothelial cells

L. F. Heinrich, D. K. Andersen, M. E. Cleasby and C. Lawson*

Department of Comparative Biomedical Sciences, Royal Veterinary College, Royal College Street, London NW1 0TU, UK

Abstract

Obesity and type 2 diabetes lead to dramatically increased risks of atherosclerosis and CHD. Multiple mechanisms converge to promote atherosclerosis by increasing endothelial oxidative stress and up-regulating expression of pro-inflammatory molecules. Microvesicles (MV) are small ($<1\,\mu m$) circulating particles that transport proteins and genetic material, through which they are able to mediate cell–cell communication and influence gene expression. Since MV are increased in plasma of obese, insulin-resistant and diabetic individuals, who often exhibit chronic vascular inflammation, and long-term feeding of a high-fat diet (HFD) to rats is a well-described model of obesity and insulin resistance, we hypothesised that this may be a useful model to study the impact of MV on endothelial inflammation. The number and cellular origin of MV from HFD-fed obese rats were characterised by flow cytometry. Total MV were significantly increased after feeding HFD compared to feeding chow ($P<0.001$), with significantly elevated numbers of MV derived from leucocyte, endothelial and platelet compartments ($P<0.01$ for each cell type). MV were isolated from plasma and their ability to induce reactive oxygen species (ROS) formation and vascular cell adhesion molecule (VCAM)-1 expression was measured in primary rat cardiac endothelial cells *in vitro*. MV from HFD-fed rats induced significant ROS ($P<0.001$) and VCAM-1 expression ($P=0.0275$), indicative of a pro-inflammatory MV phenotype in this model of obesity. These findings confirm that this is a useful model to further study the mechanisms by which diet can influence MV release and subsequent effects on cardio-metabolic health.

Key words: Microvesicles: Extracellular vesicles: Obesity: Endothelium: Inflammation: Vascular cell adhesion molecule-1: Oxidative stress

The prevalence of both obesity and type 2 diabetes (T2D) has increased dramatically in recent decades worldwide. Both conditions represent substantial risk factors for the development of atherosclerotic disease and the resulting increased incidence of myocardial infarction and stroke[1]. Atherosclerosis is a chronic inflammatory disease of the large arteries that involves in its earliest stages a non-resolving pro-inflammatory activation of the vascular endothelium, leading to platelet adherence, and activation, adhesion and trans-endothelial migration of monocyte subsets, which then differentiate into macrophages within the developing neointima[2].

The development of vascular inflammation and oxidative stress are two key mechanisms involved in endothelial dysfunction and atherosclerosis progression in obesity and T2D and both are promoted independently by hyperglycaemia and insulin resistance (IR)[3,4]. High glucose concentrations, chronic hyperinsulinaemia and obesity, all promote pro-inflammatory gene expression[5,6] and endothelial NO synthase uncoupling in endothelial cells, resulting in increased reactive oxygen species (ROS), reduced NO and a reduction in endothelial-dependent relaxation and associated vascular changes[7–9].

Extracellular vesicles are small ($<1\,\mu m$) circulating vesicles that can be classified as smaller exosomes (80–100 nm), released by an endosomal pathway[10–12] or larger, more heterogeneous microvesicles (MV; 100–1000 nm). These are released from cells including endothelial cells, leucocytes, platelets and erythrocytes by blebbing of the plasma membrane during activation and apoptosis[10–12]. Plasma MV are increased during disease processes, including cancer, CVD and autoimmunity (for reviews see Diamant *et al.*[15], Tramontano *et al.*[16], Chen *et al.*[17]). MV can be identified by the presence of exposed phosphatidyl serine on their plasma membranes and by the presence of surface markers referable to their parent cells. They can bind to cells using membrane receptors and contain 'cargo' such as proteins,

mRNA and microRNA, which they can deliver to recipient cells and thus activate intracellular signalling pathways and gene transcription. Thus, MV may be useful plasma biomarkers as well as contributing to disease processes by altering signal transduction[12].

Chronic inflammation of the endothelium may be one of the triggers for MV release from circulating cells. Our previous work demonstrated release of pro-oxidant, pro-coagulant leucocyte, platelet and erythrocyte-derived MV in whole blood flowing over inflamed endothelium that could induce ROS formation in quiescent endothelium[13,14]. Increased numbers of MV have been identified in the plasma of patients with elevated plasma LDL-cholesterol, obesity, metabolic syndrome and T2D, all of which represent risk factors for CVD[15–17].

The present study aims to determine whether a well-described rodent model of obesity and IR, which has previously been shown to have a pro-inflammatory phenotype[18], also leads to production of increased numbers of circulating pro-inflammatory MV. We used plasma obtained from rats that had been fed a high-fat diet (HFD) to identify the cellular origin of the MV released during obesity and determined whether the purified MV could directly induce pro-inflammatory changes in rat cardiac endothelial cells (RCEC).

Methods

Animal model

The present study was approved by the Royal Veterinary College's Welfare and Ethics Committee and was carried out under UK Home Office licenses to comply with the Animals (Scientific Procedures) Act 1986. Six-week-old male Wistar rats (Charles River) were maintained at $22 \pm 0.5°C$ under a 12 h light−12 h dark cycle. Ten were fed a standard mainten-ance chow diet (Special Diet Services) and ten were fed a HFD, providing 60 % energy as fat (RD12492; Research Diets) *ad libitum* for 20 weeks. An intraperitoneal insulin tol-erance test was conducted in overnight fasted rats to confirm the development of IR. Briefly, blood glucose was measured immediately prior (time = 0) to an intraperitoneal injection of 3 nmol/kg (0.5 IU/kg) insulin (Actrapid; Novo Nordisk), and 15, 30, 60 and 90 min afterwards using an Accuchek Aviva handheld glucometer (Roche). Plasma insulin concen-tration was measured using a rat insulin RIA kit (Millipore) at time 0. Body mass and epididymal fat pad mass were recorded at euthanasia.

Blood was collected by cardiac puncture under terminal anaesthesia with pentobarbitone and 1 ml was collected into tubes containing 100 μl 3.2 % sodium citrate, followed by centrifugation at 2000 ***g*** for 1 min to separate plasma. Plasma was collected, stored at −80°C and thawed on ice before use.

Materials

Phycoerythrin (PE)-IgGI k isotype control and fluorescein isothiocyanate (FITC)-IgGI k isotype control, PE anti-CD31 (PECAM-1; used as endothelial marker) and PE anti-α/β T-cell receptor (TCR; used as T cell marker) were from BD Bioscience. PE anti-CD106 (vascular cell adhesion molecule-1; VCAM-1; expressed by activated endothelial cells) was from BioLegend. PE Cy7 annexin V (AnnV; to detect exposed phosphatidyl serine), PE anti-CD45.2 (pan-leucocyte marker) and PE anti- CD61 (integrin β3; platelet marker) were from eBioscience. Fluorescein isothiocyanate anti-CD43 (pan-leu-cocyte marker apart from B Cells), PE anti-CD11b (activated leucocyte marker) and fluorescein isothiocyanate anti-macro-phage antibody were from AbDSerotec.

Latex sizing beads (1.1 μm) and Dihydrorhodamine 123 were from Sigma and enumeration beads from Bangs Laboratories (supplied by Stratech Scientific). Tissue culture medium was from PAA or Sigma. Full endothelial cell medium (EC medium) contained HEPES-buffered M199 supplemented with penicil-lin/streptomycin, 2 mM-L-glutamine, 20 % fetal calf serum, 0.55 mg/ml heparin and 275 μg/ml endothelial cell growth sup-plement. 1 × Tyrode's buffer was prepared daily (139 mM-NaCl, 3 mM-KCl, 17 mM-NaHCO$_3$, 3 mM-CaCl$_2$, 1 mM-MgCl$_2$). Annexin V Binding buffer was from eBioscience. All buffers were passed through 0.22 μm syringe filters before use.

Enumeration and phenotyping of microvesicle populations by flow cytometry

Flow cytometric analysis of the same volume of antibody-labelled plasma from each animal was carried out as described previously[13,14], using a FACS Canto II (BD Biosciences), utilising three lasers, eight colours, a standard optical filter setup and FACS Diva Software version 6.1 (BD Biosciences). The instrument was calibrated daily using Cell Tracker Beads (BD Biosciences). MV were identified by their characteristic forward (FSC-A; indicates size of particles) and side scatter (SSC-A; indicates granularity of particles) and their ability to bind to cell-specific monoclonal antibodies. Plasma samples were diluted 1:10 in Tyrode's buffer and 50 μl diluted plasma was incubated on ice with antibodies or isotype controls. After 15 min, 450 μl of Tyrode's or Annexin V binding buffer was added. 1.09 μm latex beads (Sigma) were added to each sample to allow detection of particles < 1 μm. 10 μl Absolute Count beads (Bang's Labo-ratories) were added to each sample to allow internal calibration of the number of events < 1.1 μm according to the following equation. Samples were acquired for 2 min on a low flow rate (online Supplementary Fig. S1). Isotype controls were used to adjust voltages for fluorescein isothio-cyanate, PE or Cy-7 for each sample. Negative gates were set to 1% of total counts for fluorescence. A platelet-gate was additionally plotted on the FSC/SSC plots according to the characteristic 'cloud' of light-scatter characteristic of platelet populations (online Supplementary Fig. S1(C)[13]). For each phenotypic marker, MV were counted by reference to enumeration beads:

$$\text{MV density}/\mu l = (\text{number of enumeration beads added}/ \mu l \times \text{events counted} \times \text{dilution factor})/ (\text{number of enumeration beads counted}).$$

Measurement of microvesicle-induced reactive oxygen species in rat endothelial cells using dihydrorhodamine 123

We conducted a small pilot study to determine a suitable number of pro-inflammatory MV to add using THP-1 monocytes (human monocyte cell line TIB202 available from the American Type Culture Collection) that had been differentiated with phorbol myristate acetate (PMA) 200 ng/ml for 72 h. Briefly, differentiated THP-1 (1×10^6 per well) were washed to remove non-adherent cells, and treated with 10 μg/ml lipopolysaccharide (LPS) for 24 h (medium was removed, cells washed and replaced with fresh medium after 8 h to remove traces of unbound LPS). MV were analysed by flow cytometry with enumeration beads as described in Materials and Methods. Appropriate volumes of conditioned medium from untreated or LPS-treated THP-1 macrophages equating to final concentrations of 1000, 200, 100, 50 or 10 MV/μl were centrifuged at 17 000 g for 15 min to pellet MV and re-suspended in 500 μl M199/10 % fetal calf serum. Conditioned medium (100 μl) was added to human umbilical vein endothelial cells seeded onto white opaque ninety-six well plates (2×10^4 per well) and pre-loaded with 5 μm dihydrorhodamine 123, followed by analysis on a fluorescent plate reader (Wallac Victor 2 1420) after 24 h. LPS (10 mg/ml) was added to human umbilical vein endothelial cells as a positive control (online Supplementary Fig. S3). From this we determined that a minimum of 100 MV/μl of MV released from inflamed cells was sufficient for eliciting ROS production in EC. In contrast, up to 1000 MV/μl of MV from quiescent cells had no effect on ROS.

Primary cultures of RCEC isolated from the PVG.AO-RT1[u] strain were obtained from Professor Marlene Rose (Imperial College, London) at no cost. RCEC were cultured in EC medium and seeded at 25 000 cells per well on white opaque ninety-six well plates and allowed to adhere overnight. The culture medium was replaced with EC medium containing 1 μm-dihydrorhodamine 123, followed by 10-min incubation in the dark. Meanwhile, MV were isolated by centrifugation of 50 μl of each plasma sample at 17 000 g for 15 min at 4°C. Pellets were re-suspended in 500 μl EC medium (a one in ten dilution from the original plasma; approximately 900 MV/μl from HFD-fed rats was added to the cells) and added in triplicate. Fluorescence was read at 0, 5, 10, 15, 30 min, 1, 2, 4 and 24 h on a fluorescent plate reader (Wallac Victor 2 1420 Multilabel counter; Perkin Elmer). Positive (1 nM-H_2O_2) and negative (100 μl of medium) controls were also analysed (n 4 RCEC isolates).

Measurement of CD106 (vascular cell adhesion molecule-1) expression in microvesicle-treated rat cardiac endothelial cells

RCEC were seeded at 200 000 cells per well. The following day MV were isolated by centrifugation of 50 μl (approximately 50 000 MV in total) of each plasma sample at 17 000 g for 10 min at 4°C. The supernatant was removed and the pellet (containing MV) was re-suspended in 500 μl EC medium (a one in ten dilution from the original plasma – approximately 900 MV/μl from HFD-fed rats). Medium was removed from adhered RCEC, replaced with MV-containing medium and the cells were incubated overnight at 37°C. Negative (medium alone) and positive (LPS 100 ng/ml) controls were included. RCEC were disaggregated with 1 × trypsin/EDTA for 5 min. Non-adherent cells were pelleted and incubated with anti-CD106 or isotype control antibodies on ice for 20 min, then FACS FIX (0·5 % formaldehyde in PBS) was added to each tube and samples were immediately analysed. Median fluorescence intensity for each sample was recorded (n 3 RCEC isolates).

Statistical analysis

Data analysis was carried out using GraphPad Prism version 6 (GraphPad Software). All data are means with their standard errors. A D'Agostino and Pearson omnibus normality test was carried out on all MV data and consequently all were analysed using Mann–Whitney U or Kruskal–Wallis tests followed by Dunn's multiple comparison test as appropriate. For differences between the treatment groups across time points, a two-way ANOVA was used, accompanied by the Tukey *post hoc* test where appropriate. Correlation measurements were carried out using Spearman's correlation for non-parametric data (r^2). Student's t tests were used to compare total rat and fat depot masses and plasma insulin and two-way repeated measures ANOVA for intraperitoneal insulin tolerance test data. $P < 0·05$ was accepted as significant.

Results

High-fat diet feeding-induced obesity is associated with increased phosphatidyl serine-positive microvesicle release

Feeding of a HFD for 20 weeks resulted in increased body mass (746 (SEM 20) $v.$ 523 (SEM 30) g; $P < 0·001$) and epididymal fat pad mass as a percentage of body mass (3·11 (SEM 0·17) $v.$ 1·44 (SEM 0·13) %: $P < 0·001$) $v.$ chow-fed rats, consistent with the development of obesity. Fasting plasma insulin was also increased in HFD- $v.$ chow-fed rats (5·84 (SEM 0·46) $v.$ 2·44 (SEM 0·35) ng/ml; $P < 0·001$), while blood glucose concentrations were suppressed less effectively in HFD-fed rats during an intraperitoneal insulin tolerance test (online Supplementary Fig. S2), confirming the development of IR. As shown in online Supplementary Fig. S1 and Fig. 1(a), there were 12·7-fold more MV identified in the plasma of HFD-fed rats compared with that in the plasma of chow-fed rats ($P < 0·001$). There was also an 8-fold higher Annexin V binding to MV in HFD plasma than in chow plasma ($P < 0·0001$; Fig. 1(b)), indicative of increased phosphatidyl serine exposure and loss of membrane asymmetry.

Increased numbers of CD45[+], CD43[+] or TCR[+] microvesicles are released in rat obesity

The cellular sources of MV identified in Fig. 1 were characterised using fluorescently conjugated antibodies directed against

Fig. 1. Annexin V^+ microvesicles (MV) are elevated in the plasma of rats fed a high-fat diet (HFD) for 20 weeks. MV in plasma samples from chow-fed (▤) or HFD-fed (■) rats were enumerated by flow cytometry. (a) Total MV/μl counted in each plasma sample using the gating strategy outlined in Methods and illustrated in online Supplementary Fig. S1(A). (b) Annexin V^+ MV. *n* 9–10 rats/group. Values are means, with their standard errors represented by vertical bars. *** Mean value was significantly different from that of the chow-fed group ($P < 0.001$).

CD43, CD45 or TCR, proteins expressed on the surface of leucocytes (Fig. 2). $CD45^+$ MV (pan-leucocyte marker) were 7·5-fold increased after HFD feeding ($P = 0.0029$; Fig. 2(a)). Furthermore, MV expressing CD43, a marker of T-lymphocytes and monocytes (2·5-fold, $P = 0.0354$; Fig. 2(b)), the antigen recognised by MAC387 (a monocyte marker; 22-fold, $P = 0.0018$; Fig. 2(c)), αβ TCR (17·3-fold, $P < 0.0001$; Fig. 2(d)) and CD11b (2·0-fold, $P = 0.0147$; Fig. 2(e)), were all increased in obese rat plasma, indicating an effect of HFD feeding on all major classes of leucocyte-derived MV, including those released by activated cells. Furthermore, there was a significant correlation between blood glucose level and numbers of $MAC387^+$ MV (r 0·789, $P = 0.007$) in HFD-fed rats (Fig. 2(f)).

Platelet and endothelial cell-derived microvesicles are increased in plasma from obese rats

As shown in Fig. 3, plasma from HFD-fed rats contained 9·4-fold more endothelial cell-derived $CD31^+$ MV/μl, compared to chow-fed rats ($P = 0.0185$; Fig. 3(a)). In addition, VCAM-1^+ MV, derived from activated EC, tended to be increased in HFD- *v.* chow-fed rats (by 73 %, $P = 0.088$; Fig. 3(b)). Surprisingly, Annexin V^+ platelet-derived MV ($CD61^+$) appeared to be very rare in plasma from chow-fed rats (4 (SEM 1) MV/μl), but were markedly more abundant in HFD plasma (1055 (SEM 609) MV/μl, $P = 0.0039$), therefore we reanalysed the data to include both Ann V^+ and Ann V^- $CD61^+$ MV (174 (SEM 105) in chow-fed *v.* 1570 (SEM 1277) in HFD-fed plasma $P = 0.0281$; Fig. 3(c)). To confirm that platelet-derived MV were increased, the FSC/SSC plots were re-analysed to determine the number of $CD61^+$ ($AnnV^+$ and Ann V^-) MV

in the classic platelet cloud (129 (SEM 51·0) $CD61^+$ MV/μl in chow- and 349 (SEM 105) in HFD-fed rat plasma; $P = 0.0039$; online Supplementary Fig. S1(C), Fig. 3(d)). There were significant correlations between blood glucose level and numbers of both $CD31^+$ MV (r^2 0·645, $P = 0.044$) and $CD61^+$ MV (r^2 0·541, $P = 0.0153$) in HFD-fed rats (Fig. 3(e) and (f)).

Exposure of quiescent endothelial cells to microvesicles derived from obese rats induces vascular cell adhesion molecule-1 expression

VCAM-1 (CD106) is expressed by cytokine-activated endothelium and is a marker of inflammation[2]. As shown in Fig. 4, incubation of RCEC with MV derived from plasma of HFD-fed rats but not from chow-fed rats induced an increase in VCAM-1 median fluorescence intensity on the cell surface to a similar extent to that induced by positive control LPS treatment (VCAM-1 increased by 59 % in HFD *v.* chow endothelium; $P = 0.0275$).

Exposure of quiescent endothelial cells to microvesicles derived from obese rats induces reactive oxygen species formation

ROS formation was measured over 24 h using dihydrorhodamine 123. At all time points H_2O_2 treatment led to increased ROS formation *v.* either control or addition of MV, as expected

Fig. 2. Leucocyte-derived microvesicles (MV) are increased in the plasma of rats fed a high-fat diet (HFD) for 20 weeks. MV with leucocyte surface markers were enumerated by flow cytometry in plasma samples from chow-fed (▤) or HFD fed (■) rats. (a) $CD45^+$ MV (pan-leucocyte marker). (b) $CD43^+$ MV (all leucocytes except for B cells). (c) Monocyte-derived MV (MAC387 antigen$^+$). (d) TCR^+ MV (T-cell marker). (e) $CD11b^+$ MV (activated leukocytes). *n* 9–10 rats/group. Values are means, with their standard errors represented by vertical bars. Mean value was significantly different from that of the chow-fed group: * $P < 0.05$, ** $P < 0.01$, **** $P < 0.0001$. (f) Correlation of $MAC387^+$ MV with glucose (mM). ■, $MAC387^+$ MV HFD; ▤, $MAC387^+$ MV chow. R 0·089 $P = 0.007$.

Fig. 3. CD31$^+$ and CD61$^+$ microvesicles (MV) are raised in the plasma of rats fed a high-fat diet (HFD) for 20 weeks. CD31$^+$ (endothelial) MV (a, b) or CD61$^+$(platelet) (c, d) surface markers were enumerated by flow cytometry in plasma samples from chow-fed (▨) or HFD-fed (■) rats. (a) CD31$^+$ MV (endothelial cell marker). (b) CD106$^+$ MV (activated endothelial cells). (c) CD61$^+$ MV (platelets). (D) CD61$^+$ MV in platelet gate illustrated in online Supplementary Fig. S1(C). n 9–10 rats/group. Values are means, with their standard errors represented by vertical bars. Mean value was significantly different from that of the chow-fed group: * $P < 0.05$, ** $P < 0.01$. † Mean value was marginally significantly different from that of the chow-fed group ($P < 0.1$). (e) Correlation of CD31$^+$ MV in HFD plasma and glucose R 0.645 $P = 0.044$. –●–, CD31$^+$ MV HFD; –■–, CD31$^+$ MV chow. (f) Correlation of CD61$^+$ MV in HFD plasma with glucose (mM). –■–, CD61$^+$ MV chow; –▲–, CD61$^+$ MV HFD. R^2 0.541, $P = 0.0153$.

(Fig. 5). However, after 24-h treatment, ROS production was increased in HCEC treated with MV from HFD-fed rats compared with the untreated control or chow MV (30 % increase in HFD *v.* chow; $P < 0.0001$).

Discussion

There is a growing literature demonstrating that chronic diseases with an inflammatory component are characterised by increased release of MV into plasma. In the present study, we have used a well-characterised rodent model to show that obesity is associated with substantially elevated numbers of circulating MV, in agreement with data from recent studies of human obesity and diabetes[15–17,19–21]. In addition, phenotypic analysis of these MV revealed that they were derived from endothelial cells (CD31$^+$), platelets (CD61$^+$), T cells (TCRα/β) and monocytes (MAC387$^+$) – key cell populations involved in the initiation and progression of atherosclerosis whose numbers are also elevated in human cardio-metabolic disease[17,22,23]. Furthermore, the numbers of MV correlated with the glucose levels in these animals, again consistent with human studies[23]. Recent studies (e.g. do Carmo et al.[24]) suggest that long-term feeding of a HFD leads to bone marrow hyperplasia and modulation of haematopoiesis, which in turn leads to higher numbers of circulating leucocytes, which could at least in part account for the observed increase in circulating leucocyte MV in the HFD-fed rats.

Interestingly, we found a large proportion of the CD61$^+$ MV did not bind Annexin V, suggesting that HFD led to an increase in platelet MV release due to increased turnover as has been described in human samples[25] rather than activation and release of procoagulant MV.

The overall numbers of platelet-derived MV detected are in agreement with another recent study carried out in streptozotocin-treated rats[26]. Interestingly, another study that subjected younger rats (13 weeks old rather than 26 weeks old) to hypoxia described much higher numbers of platelet-derived MV, both in control and in hypoxia-exposed animals[27]. This may reflect an age-dependent decline in the release of MV from platelets in the rat, although this possibility awaits confirmation.

MV were able to elicit pro-inflammatory effects in quiescent endothelial cells, a finding consistent with the existing theory that circulating MV do not merely represent a mechanism to remove cellular debris from dying or activated cells, but have functional importance in transcellular communication during the progression of chronic inflammatory diseases, and may be important for increasing endothelial dysfunction in plaque-prone areas, a pre-requisite for atheroma formation[10]. The present work also highlights the usefulness of this rodent model to further study the influence of diet on MV release and the effects of MV on vascular inflammation. To our knowledge, this is the first study to demonstrate the potential functional importance of elevated numbers of MV observed in obesity for inciting endothelial inflammatory responses. However, although we have shown a relationship between plasma glucose and numbers of various MV subsets, it is unclear as yet which of the obesity-associated metabolic, endocrine or pro-inflammatory changes may be responsible for the increased MV generation.

MV derived from cells of monocyte/macrophage lineage, T cells, endothelial cells and platelets have been identified in human atherosclerotic lesions[28] and shown to contribute

Fig. 4. CD106 (vascular cell adhesion molecule-1 (VCAM-1)) expression is increased on endothelial cells treated with microvesicles (MV) from high-fat diet (HFD) fed rats. MV from chow-fed rats (▨) or HFD-fed rats (■) for 20 weeks were isolated from plasma by centrifugation at 17 000 *g* and used to stimulate primary cultures of rat cardiac endothelial cells for 18 h. VCAM-1 mean fluorescence intensity (MFI) on rat cardiac endothelial cells surface was analysed by flow cytometry. 10 ng/ml lipopolysaccharide (LPS) used as a positive control (hatched), n 3 RCEC isolates. Values are means, with their standard errors represented by vertical bars. * Mean value was significantly different from that of the chow-fed group ($P < 0.05$). a.u., Arbitrary units.

Fig. 5. Reactive oxygen species (ROS) induction in rat endothelial cells by microvesicles (MV) from chow- or high-fat diet (HFD)-fed rats. MV were isolated from plasma by centrifugation at 17 000 *g* and used to stimulate primary cultures of rat cardiac endothelial cells that had been loaded with dihydrorhodamine 123. MV from rats fed chow (−▽−) or HFD (−▼−) for 20 weeks. 1 nM-hydrogen peroxide used as a positive control (−■−), untreated (−●−); *n* 4 RCEC isolates. Two-way non-parametric ANOVA followed by Tukey. Values are means, with their standard errors represented by vertical bars. **** Mean value was significantly different from that of the chow-fed group at 24 h after treatment ($P < 0.0001$). ‡‡‡‡ Mean values for the hydrogen peroxide-treated group were significantly higher than for all other groups at all time points ($P < 0.0001$).

to plaque instability, in part by promoting monocyte adhesion and trans-endothelial migration via enhanced surface expression of endothelial intercellular adhesion molecule-1[29]. In the present study, MV derived from HFD-fed rats induced VCAM-1 expression, which is another key adhesion molecule involved in firm adhesion and trans-endothelial migration of monocytes in rodent models of atherosclerosis[30]. Further work is required to determine the full extent of pro-inflammatory gene expression up-regulated by MV derived from HFD- *v.* chow-fed rats.

It is likely that the individual species of MV present in the mixed populations isolated from patients or animal models have disparate effects, but together have a net pro- or anti-atherogenic effect on endothelia. Further work is required to dissect the responses elicited by individual MV species in order to fully understand how they contribute to vascular inflammation and atherosclerosis. However, it is still not technically possible to satisfactorily separate *in vivo* generated MV to determine their function. We have previously developed an *in vitro* flow system to model interactions between blood and inflamed endothelium under haemodynamic flow conditions and showed that this leads to enhanced release of MV from leucocytes, platelets and erythrocytes. Furthermore, these MV were able to induce ROS in quiescent endothelium, suggesting that they are similar to *in vivo* generated MV[13,14]. Using isolated blood cells from animals fed a defined HFD or from T2D patients, and autologous isolated endothelial cells (rodent) or explanted blood vessels (from diabetic peripheral arterial disease amputees) it should in future be possible to determine more accurately the role of individual species of MV in endothelial dysfunction.

One of the limitations to the present study is that only one subset of extracellular vesicles was measured, namely, the MV population >200 nm in diameter, due to difficulties

distinguishing smaller particles from background noise by conventional flow cytometry. It is likely that in addition to release of the larger MV there is also increased production of pro-inflammatory exosomes and smaller (<200 nm) MV, in development of obesity and IR in this rodent model in agreement with human studies[31]. A number of methods for exosome measurement and isolation have been described recently, including Nanotracking analysis and dynamic light scattering (for review see Yellon & Davidson[32], Mulcahy *et al.*[33]). However, at the present time, it is not possible to identify the cellular sources of exosomes, and nanotracking analysis and DLA do not easily enable identification of the cellular source of MV, thus flow cytometric analysis is currently the most established technology for immune-phenotyping of MV released by inflamed and activated cells. In addition, we utilised frozen and thawed plasma samples. Recent studies by several groups have recommended analysis of fresh plasma or whole blood for extracellular vesicle analysis; however, use of citrate as anti-coagulant followed by freezing of plasma at −80°C has been shown to be an acceptable alternative (for recent reviews see Lacroix *et al.*[34], van der Meel *et al.*[35]). We used MV from a similar volume of plasma from HFD- or chow-fed rats for our functional studies. This was based on pilot studies with MV derived from single (human) cell types in tissue culture experiments, which suggested that the number of MV added is not a significant factor for their pro-inflammatory or other effects (online Supplementary Fig. S3), but instead the stimulus that has been used to generate the MV is more important. A similar approach has been taken in other studies where numbers of MV approximating to those found circulating have been added[27].

Obesity and IR induce oxidative stress and inflammation in the endothelium, features of endothelial dysfunction that predispose to atherosclerotic lesion formation[3,4]. Furthermore, endothelial cells from T2D patients display defective insulin signalling, increased nitrotyrosine, ROS and increased NF-κB p65 and intercellular adhesion molecule-1 expression[36]. It is possible that increased VCAM-1 expression is mediated by the observed ROS production, which might be downstream of RAC activation (for review see Marcos-Ramiro *et al.*[37]). Although limitations in the plasma sample volume collected from each animal prevented us from investigating this mechanism during the present study, it could be investigated using ROS scavengers or dominant negative RAC constructs in *in vitro* experiments. It is likely that these effects are also mediated at least in part by chronic activation of protein kinase C, which has been described in micro- and macro-vascular tissue and circulating leucocytes in human T2D and rodent models[36].

In agreement with this, protein kinase C is activated during culture of rat aortic endothelial cells, smooth muscle cells and circulating monocytes in hyperglycaemic conditions[38]. Protein kinase C activation is associated with phosphatidyl serine externalisation and CD43 expression on MV in neutrophils[39], suggesting a direct link between IR and increased levels of circulating MV. Endothelial and platelet-derived MV identified in the plasma of patients with metabolic

syndrome have also been shown to have a pro-oxidant effect on endothelium, inducing NO and ROS production[40].

Hyperglycaemia and impaired insulin signalling leading to endothelial inflammation and protein kinase C activation could contribute to the increased numbers of circulating MV observed in obese rats and human subjects. Moreover, given that oxidative stress and pro-inflammatory gene expression are key characteristics of diabetic endothelial dysfunction[3,4] and our findings that MV from HFD-fed rats lead to increases in both ROS and VCAM-1 expression, we and others have proposed that MV released from multiple cell types under diabetogenic conditions are functional particles that contribute to systemic vascular inflammation and endothelial dysfunction, leading to macrovascular changes and potentially the accelerated atherosclerotic lesion progression that is observed in T2D[17,22,23]. Further work is required to determine the exact mechanisms leading to MV release under diabetogenic conditions, and the rat model used in the present study may prove useful to help determine how MV release and their functional properties can be altered in a physiologically relevant *in vivo* context, in response to dietary composition or therapeutic substances.

Supplementary material

To view supplementary material for this article, please visit http://dx.doi.org/10.1017/S0007114515001117

Acknowledgements

References

1. Grundy SM, Pasternak R, Greenland P, *et al.* (1999) Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. *Circulation* **100**, 1481–1492.
2. Libby P, Lichtman AH & Hansson GK (2013) Immune effector mechanisms implicated in atherosclerosis: from mice to humans. *Immunity* **38**, 1092–1104.
3. Hartge MM, Unger T & Kintscher U (2007) The endothelium and vascular inflammation in diabetes. *Diab Vasc Dis Res* **4**, 84–88.
4. Mazzone T, Chait A & Plutzky J (2008) Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies. *Lancet* **371**, 1800–1809.
5. Hotamisligil GS, Peraldi P, Budavari A, *et al.* (1996) IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α- and obesity-induced insulin resistance. *Science* **271**, 665–668.
6. Bastard JP, Maachi M, Lagathu C, *et al.* (2006) Recent advances in the relationship between obesity, inflammation, and insulin resistance. *Eur Cytokine Netw* **17**, 4–12.
7. Yan SD, Schmidt AM, Anderson GM, *et al.* (1994) Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. *J Biol Chem* **269**, 9889–9897.
8. Gao L & Mann GE (2009) Vascular NAD(P)H oxidase activation in diabetes: a double-edged sword in redox signalling. *Cardiovasc Res* **82**, 9–20.
9. Son SM (2012) Reactive oxygen and nitrogen species in pathogenesis of vascular complications of diabetes. *Diabetes Metab J* **36**, 190–198.
10. van der Pol E, Böing AN, Harrison P, *et al.* (2012) Classification, functions, and clinical relevance of extracellular vesicles. *Pharmacol Rev* **64**, 676–705.
11. Dignat-George F & Boulanger CM (2011) The many faces of endothelial microparticles. *Arterioscler Thromb Vasc Biol* **31**, 27–33.
12. Théry C, Ostrowski M & Segura E (2009) Membrane vesicles as conveyors of immune responses. *Nat Rev Immunol* **9**, 581–593.
13. Macey MG, Wolf SI & Lawson C (2010) Microparticle formation after exposure of blood to activated endothelium under flow. *Cytometry A* **77**, 761–768.
14. Holtom E, Usherwood JR, Macey MG, *et al.* (2012) Microparticle formation after co-culture of human whole blood and umbilical artery in a novel *in vitro* model of flow. *Cytometry A* **81**, 390–399.
15. Diamant M, Nieuwland R, Pablo RF, *et al.* (2002) Elevated numbers of tissue-factor exposing microparticles correlate with components of the metabolic syndrome in uncomplicated type 2 diabetes mellitus. *Circulation* **106**, 2442–2447.
16. Tramontano AF, Lyubarova R, Tsiakos J, *et al.* (2010) Circulating endothelial microparticles in diabetes mellitus. *Mediators Inflamm* **2010**, 250476.
17. Chen Y, Feng B, Li X, *et al.* (2012) Plasma endothelial microparticles and their correlation with the presence of hypertension and arterial stiffness in patients with type 2 diabetes. *J Clin Hypertens (Greenwich)* **14**, 455–460.
18. Sena CM, Matafome P, Louro T, *et al.* (2011) Metformin restores endothelial function in aorta of diabetic rats. *Br J Pharmacol* **163**, 424–437.
19. Stepanian A, Bourguignat L, Hennou S, *et al.* (2013) Microparticle increase in severe obesity: not related to metabolic syndrome and unchanged after massive weight loss. *Obesity (Silver Spring)* **21**, 2236–2243.
20. Cheng V, Kashyap SR, Schauer PR, *et al.* (2013) Restoration of glycemic control in patients with type 2 diabetes mellitus after bariatric surgery is associated with reduction in microparticles. *Surg Obes Relat Dis* **9**, 207–212.
21. Zhang X, McGeoch SC, Johnstone AM, *et al.* (2014) Platelet-derived microparticle count and surface molecule expression differ between subjects with and without type 2 diabetes, independently of obesity status. *J Thromb Thrombolysis* **37**, 455–463.
22. Feng B, Chen Y, Luo Y, *et al.* (2010) Circulating level of microparticles and their correlation with arterial elasticity and endothelium-dependent dilation in patients with type 2 diabetes mellitus. *Atherosclerosis* **208**, 264–269.
23. Kranendonk ME, de Kleijn DP, Kalkhoven E, *et al.* (2014) Extracellular vesicle markers in relation to obesity and metabolic complications in patients with manifest cardiovascular disease. *Cardiovasc Diabetol* **13**, 37.
24. do Carmo LS, Rogero MM, Paredes-Gamero EJ, *et al.* (2013) A high-fat diet increases interleukin-3 and granulocyte colony-stimulating factor production by bone marrow cells and triggers bone marrow hyperplasia and neutrophilia in Wistar rats. *Exp Biol Med (Maywood)* **238**, 375–384.

25. Connor DE, Exner T, Ma DD, *et al.* (2010) The majority of circulating platelet-derived microparticles fail to bind annexin V, lack phospholipid-dependent procoagulant activity and demonstrate greater expression of glycoprotein Ib. *Thromb Haemost* **103**, 1044–1052.

26. Hosseinzadeh S, Zahmatkesh M, Zarrindast MR, *et al.* (2013) Elevated CSF and plasma microparticles in a rat model of streptozotocin-induced cognitive impairment. *Behav Brain Res* **256**, 503–511.

27. Tual-Chalot S, Guibert C, Muller B, *et al.* (2010) Circulating microparticles from pulmonary hypertensive rats induce endothelial dysfunction. *Am J Respir Crit Care Med* **182**, 261–268.

28. Canault M, Leroyer AS, Peiretti F, *et al.* (2007) Microparticles of human atherosclerotic plaques enhance the shedding of the tumor necrosis factor-α converting enzyme/ADAM17 substrates, tumor necrosis factor and tumor necrosis factor receptor-1. *Am J Pathol* **171**, 1713–1723.

29. Rautou PE, Leroyer AS, Ramkhelawon B, *et al.* (2011) Microparticles from human atherosclerotic plaques promote endothelial ICAM-1-dependent monocyte adhesion and transendothelial migration. *Circ Res* **108**, 335–343.

30. Iiyama K, Hajra L, Iiyama M, *et al.* (1999) Patterns of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 expression in rabbit and mouse atherosclerotic lesions and at sites predisposed to lesion for mation. *Circ Res* **85**, 199–207.

31. Ferrante SC, Nadler EP, Pillai DK, *et al.* (2015) Adipocyte-derived exosomal miRNAs: a novel mechanism for obesity-related disease. *Pediatr Res* **77**, 447–454.

32. Yellon DM & Davidson SM (2014) Exosomes: nanoparticles involved in cardioprotection? *Circ Res* **114**, 325–332.

33. Mulcahy LA, Pink RC & Carter DR (2014) Routes and mechanisms of extracellular vesicle uptake. *J Extracell Vesicles* (Epublication ahead of print version 4 August 2014).

34. Lacroix R, Judicone C, Mooberry M, *et al.* (2013) Standardization of pre-analytical variables in plasma microparticle determination: results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop. *J Thromb Haemost* **11**, 1190–1193.

35. van der Meel R, Krawczyk-Durka M, van Solinge WW, *et al.* (2014) Toward routine detection of extracellular vesicles in clinical samples. *Int J Lab Hematol* **36**, 244–253.

36. Tabit CE, Shenouda SM, Holbrook M, *et al.* (2013) Protein kinase C-β contributes to impaired endothelial insulin signaling in humans with diabetes mellitus. *Circulation* **127**, 86–95.

37. Marcos-Ramiro B, García-Weber D & Millán J (2014) TNF-induced endothelial barrier disruption: beyond actin and Rho. *Thromb Haemost* **112**, 1088–1102.

38. Das Evcimen N & King GL (2007) The role of protein kinase C activation and the vascular complications of diabetes. *Pharmacol Res* **55**, 498–510.

39. Nusbaum P, Lainé C, Bouaouina M, *et al.* (2005) Distinct signaling pathways are involved in leukosialin (CD43) down-regulation, membrane blebbing, and phospholipid scrambling during neutrophil apoptosis. *J Biol Chem* **280**, 5843–5853.

40. Agouni A, Ducluzeau PH, Benameur T, *et al.* (2011) Microparticles from patients with metabolic syndrome induce vascular hypo-reactivity via Fas/Fas-ligand pathway in mice. *PLoS ONE* **6**, e27809.